Liquidia (NASDAQ:LQDA) Director Katherine Rielly-Gauvin Sells 36,789 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) Director Katherine Rielly-Gauvin sold 36,789 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $74.99, for a total value of $2,758,807.11. Following the completion of the sale, the director directly owned 44,637 shares in the company, valued at $3,347,328.63. This represents a 45.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Katherine Rielly-Gauvin also recently made the following trade(s):

• On Thursday, August 20th, Katherine Rielly-Gauvin sold 18,393 shares of Liquidia stock. The shares were sold at an average price of $72.23, for a total value of $1,328,526.39.

Liquidia Stock Performance

Shares of LQDA traded down $2.43 during midday trading on Friday, hitting $68.62. 1,698,657 shares of the stock traded hands, compared to its average volume of 1,793,328. The business’s 50 day moving average price is $79.34 and its two-hundred day moving average price is $56.13. The firm has a market capitalization of $6.14 billion, a PE ratio of 50.09 and a beta of 0.58. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. Liquidia Corporation has a 1-year low of $21.15 and a 1-year high of $93.61.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The firm had revenue of $171.68 million during the quarter, compared to analyst estimates of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The firm’s revenue was up 1842.1% on a year-over-year basis. During the same period last year, the business earned ($0.49) EPS. Equities research analysts predict that Liquidia Corporation will post 2.57 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on LQDA. Needham & Company LLC boosted their target price on shares of Liquidia from $70.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a report on Friday, July 17th. Wells Fargo & Company lifted their price target on shares of Liquidia from $62.00 to $108.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Piper Sandler set a $129.00 price target on Liquidia in a report on Friday, July 24th. Finally, Lifesci Capital downgraded Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 price objective for the company. in a research report on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Liquidia has a consensus rating of “Hold” and a consensus price target of $98.08.

Institutional Investors Weigh In On Liquidia

Large investors have recently made changes to their positions in the company. GSA Capital Partners LLP increased its holdings in shares of Liquidia by 63.6% in the 4th quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock valued at $2,179,000 after purchasing an additional 24,555 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Liquidia by 63.3% during the first quarter. The Manufacturers Life Insurance Company now owns 58,265 shares of the company’s stock worth $2,199,000 after purchasing an additional 22,592 shares during the period. State of New Jersey Common Pension Fund D acquired a new stake in shares of Liquidia during the fourth quarter worth approximately $709,000. WCG Wealth Advisors LLC grew its position in Liquidia by 98.2% during the fourth quarter. WCG Wealth Advisors LLC now owns 54,411 shares of the company’s stock valued at $1,877,000 after purchasing an additional 26,957 shares in the last quarter. Finally, Handelsbanken Fonder AB purchased a new position in Liquidia during the second quarter valued at approximately $1,993,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).